Please assess the completion status of the following clinical trial:

Trial Title: Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has given written informed consent before any trial-related activity is performed~* Has a confirmed prostate cancer in which this type of treatment is needed.~Exclusion Criteria:~* Previous treatment for prostate cancer~* Previous trans-urethral resection of the prostate~* Current use of 5-alpha reductase inhibitor or α-adrenoceptor antagonist.~* Patients in need of external beam radiotherapy to be started at the same time as hormone therapy~* Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)~* History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.~* Hypersensitivity towards any component of the investigational product~* Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.~* Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/80 mg (Type: EXPERIMENTAL): Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
- Goserelin (3.6 mg) + bicalutamide (50 mg) (Type: ACTIVE_COMPARATOR): Goserelin (3.6 mg) + bicalutamide (50 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).